Celebrex and Motrin and Heart Attack Risk

Both Celebrex and Motrin family medications increase the risk of heart attacks by 40%. Interestingly, Naproxen (Alleve, Naprosyn) did not increase heart attack risk. Motrin families like Motrin cause 16,500 deaths a year from stomach bleeds as well. Because of this, and because the natural remedies are both safer and more effective, I recommend these instead (for more information, see "Arthritis? A 6 Week Program to Help Heal Your Achy Joints").

More information (as well as the scientific references for the studies cited in this article) can be found in my book Pain Free 1-2-3 (McGraw Hill, 2006).

Reference: Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 13, No. 1, 41-50 (2008) DOI: 10.1177/1074248407312990

Cyclooxygenase-2 Inhibitors and Most Traditional Nonsteroidal Anti-inflammatory Drugs Cause Similar Moderately Increased Risks of Cardiovascular Disease

Charles H. Hennekens, M.D.

Department of Clinical Science and Medical Education & Center of Excellence, Charles E. Schmidt College of Biomedical Science, Florida Atlantic University, Boca Raton, Chenneke@fau.edu , Departments of Medicine & Epidemiology and Public Health, Miller School of Medicine, University of Miami, Miami, Department of Preventive Medicine, University College of Medicine

Steven Borzak, M.D.

E. Schmidt College of Biomedical Science, Florida Atlantic University, Boca Raton, Department of Medicine NOVA Southeastern University College of Medicine, Ft. Lauderdale, Florida

Cyclooxygenase-2 inhibitors relieve pain from inflammatory conditions by decreasing the gastrointestinal side effects from traditional nonsteroidal anti-inflammatory drugs. Basic research provided plausible mechanisms and some observational epidemiological studies, case-control and cohort, indicated that patients prescribed with cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory drugs had increased risks for myocardial infarction and stroke. Because patients prescribed with cyclooxygenase-2 inhibitors were systematically different, uncontrolled and uncontrollable confounding by indication was as large as the observed risks. Thus, epidemiological studies or their meta-analyses could not discern whether, and if so, how much, the risks were real. A comprehensive meta-analysis of randomized trials indicated that cyclooxygenase-2 inhibitors increased the risk of vascular events by 42%, almost exclusively myocardial infarction, as did high-dose regimens of ibuprofen and diclofenac, but not naproxen. Individual clinical judgments and policy decisions should include cardiovascular disease and noncardiovascular disease risks including gastrointestinal side effects and clinical benefits including improved quality of life from less pain and disability.

Reference:

http://cpt.sagepub.com/cgi/content/abstract/13/1/41?&searchid=1&usestric...